Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis
- PMID: 1700828
- PMCID: PMC248749
- DOI: 10.1128/JVI.64.12.5869-5873.1990
Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis
Abstract
The ability of complement to inactivate human immunodeficiency virus (HIV) in the presence of specific antibody was evaluated. HIV was treated with complement and/or antibody, and then its titer was determined on the CD4+ H9 cell line. While complement alone had no effect on the HIV titer, complement plus subneutralizing levels of antibody resulted in titer reductions. Complement sources deficient in membrane attack component C5 or C8 did not inactivate antibody-treated HIV, suggesting that neutralization occurred via lysis. This possibility was investigated by assessing release of reverse transcriptase (RT) from the virion. Antibody plus complement, but neither reagent alone, released RT from HIV in a dose-dependent manner. Release of RT did not occur with C5- or C8-deficient sera, also indicating a requirement for membrane attack components. These studies show that complement can neutralize HIV via the classical complement pathway and that this neutralization occurs via C5b-9-mediated viral lysis. Thus, complement may play a major role in resistance to disease by lysing HIV and preventing infection of Fc- and complement receptor-positive cells, as well as CD4+ cells.
Similar articles
-
Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.J Virol. 1995 Apr;69(4):2393-400. doi: 10.1128/JVI.69.4.2393-2400.1995. J Virol. 1995. PMID: 7884885 Free PMC article.
-
Enhanced neutralization of feline immunodeficiency virus by complement viral lysis.Vet Immunol Immunopathol. 1993 Apr;36(3):191-206. doi: 10.1016/0165-2427(93)90019-z. Vet Immunol Immunopathol. 1993. PMID: 7685130
-
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.Virology. 1988 Dec;167(2):433-41. Virology. 1988. PMID: 2849234
-
The role of antibody and complement in the control of viral infections.J Invest Dermatol. 1984 Jul;83(1 Suppl):121s-127s. doi: 10.1111/1523-1747.ep12281847. J Invest Dermatol. 1984. PMID: 6376646 Review.
-
Role of humoral factors in the progression of HIV disease.Immunol Today. 1995 Apr;16(4):167-9. doi: 10.1016/0167-5699(95)80114-6. Immunol Today. 1995. PMID: 7734041 Review. No abstract available.
Cited by
-
Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.EMBO Rep. 2020 Feb 5;21(2):e49351. doi: 10.15252/embr.201949351. Epub 2019 Dec 12. EMBO Rep. 2020. PMID: 31833228 Free PMC article.
-
Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.J Virol. 1996 Aug;70(8):5236-45. doi: 10.1128/JVI.70.8.5236-5245.1996. J Virol. 1996. PMID: 8764033 Free PMC article.
-
Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).J Exp Med. 1996 Jan 1;183(1):307-10. doi: 10.1084/jem.183.1.307. J Exp Med. 1996. PMID: 8551237 Free PMC article.
-
The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients.Clin Exp Immunol. 1995 May;100(2):219-22. doi: 10.1111/j.1365-2249.1995.tb03656.x. Clin Exp Immunol. 1995. PMID: 7743658 Free PMC article.
-
Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.J Virol. 1995 Apr;69(4):2393-400. doi: 10.1128/JVI.69.4.2393-2400.1995. J Virol. 1995. PMID: 7884885 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous